Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-694-6200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.35 million
Profitability
Miscellaneous
Employees108
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions
What is Arcus Biosciences' stock symbol?
Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."
How were Arcus Biosciences' earnings last quarter?
Arcus Biosciences Inc (NYSE:RCUS) issued its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.64) EPS for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.24. The company earned $1.75 million during the quarter, compared to the consensus estimate of $4.54 million. Arcus Biosciences had a negative return on equity of 30.67% and a negative net margin of 736.31%. View Arcus Biosciences' Earnings History.
When is Arcus Biosciences' next earnings date?
What price target have analysts set for RCUS?
4 brokers have issued twelve-month target prices for Arcus Biosciences' stock. Their predictions range from $15.00 to $22.00. On average, they anticipate Arcus Biosciences' stock price to reach $19.00 in the next year. This suggests a possible upside of 172.2% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.
What is the consensus analysts' recommendation for Arcus Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.
Has Arcus Biosciences been receiving favorable news coverage?
News stories about RCUS stock have been trending positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arcus Biosciences earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for Arcus Biosciences.
Are investors shorting Arcus Biosciences?
Arcus Biosciences saw a decline in short interest in July. As of July 15th, there was short interest totalling 1,609,100 shares, a decline of 36.3% from the June 15th total of 2,527,800 shares. Based on an average trading volume of 170,000 shares, the days-to-cover ratio is presently 9.5 days. Approximately 6.3% of the company's shares are short sold. View Arcus Biosciences' Current Options Chain.
Who are some of Arcus Biosciences' key competitors?
Some companies that are related to Arcus Biosciences include AnaptysBio (ANAB), Phibro Animal Health (PAHC), Opko Health (OPK), Epizyme (EPZM), Gossamer Bio (GOSS), Athenex (ATNX), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Innoviva (INVA), Radius Health (RDUS), Odonate Therapeutics (ODT), ArQule (ARQL), Esperion Therapeutics (ESPR), Amphastar Pharmaceuticals (AMPH) and Stoke Therapeutics (STOK).
What other stocks do shareholders of Arcus Biosciences own?
Who are Arcus Biosciences' key executives?
Arcus Biosciences' management team includes the folowing people:
- Dr. Terry Rosen Ph.D., Co-Founder, Chairman & CEO (Age 59)
- Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 61)
- Mr. Steven Chan, Consultant (Age 47)
- Ms. Rekha Hemrajani, Chief Operating & Financial Officer (Age 49)
- Dr. Stephen Young Ph.D., VP of Technology (Age 50)
When did Arcus Biosciences IPO?
(RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.
Who are Arcus Biosciences' major shareholders?
Arcus Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.88%), EcoR1 Capital LLC (3.25%), Vanguard Group Inc. (2.38%), JPMorgan Chase & Co. (1.16%), Northern Trust Corp (0.72%) and Artal Group S.A. (0.61%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.
Which major investors are selling Arcus Biosciences stock?
RCUS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Artal Group S.A., Wells Fargo & Company MN, MML Investors Services LLC, Charles Schwab Investment Management Inc. and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Arcus Biosciences.
Which major investors are buying Arcus Biosciences stock?
RCUS stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, BlackRock Inc., Morgan Stanley, Citadel Advisors LLC, JPMorgan Chase & Co., Cubist Systematic Strategies LLC, White Pine Investment CO and Northern Trust Corp. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.
How do I buy shares of Arcus Biosciences?
Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arcus Biosciences' stock price today?
One share of RCUS stock can currently be purchased for approximately $6.98.
How big of a company is Arcus Biosciences?
Arcus Biosciences has a market capitalization of $320.03 million and generates $8.35 million in revenue each year. The company earns $-49,590,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.View Additional Information About Arcus Biosciences.
What is Arcus Biosciences' official website?
How can I contact Arcus Biosciences?
Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]
MarketBeat Community Rating for Arcus Biosciences (NYSE RCUS)
MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote "Outperform" if you believe RCUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
